What the literature
just published.

A Multicentre, Prospective, Randomized, Open-label, Blinded Endpoint, Pilot Clinical Trial Evaluating Subcutaneous Semaglutide in Patients With Acute Ischaemic Stroke Due to Anterior Circulation Large Vessel Occlusion Treated With Endovascular Thrombectomy

2026-10-31

Endovascular thrombectomy (EVT) is a procedure that improves recovery for people who suffer from a stroke by removing blood clots from large blood vessels in the brain. However, even with this treatment, over half of the patients either pass away or are left with serious disabilities within three months. This is partly because, even in cases of a successful EVT, brain tissue damage continues to grow. Extent of brain damage is a major factor in how well a patient recovers. Studies in animals have shown that a drug called semaglutide might help protect the brain and improve recovery after a stro

A Multicentre, Randomised, Double-blind, Placebo-controlled 52-week, Phase IIIb Trial to Evaluate the Efficacy and Safety of Survodutide in Peri- and Post-menopausal Women With Overweight or Obesity (SYNCHRONIZE®-HERA)

2026-10-31

This study is open to women up to 65 years of age who are living with overweight or obesity and are going through or have finished menopause. People can join this study if they have a Body Mass Index (BMI) of 30 kg/m² or more, or if their BMI is 27 kg/m² or more and they have one or more weight related health problems. Participants must also have tried to lose weight by dieting at least once in the past without success. People with pre-existing diabetes cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps women with overweight or

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity

2026-03-02

The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity

A Phase Ib Clinical Trial, Using Interleukin-2 (IL-2) and Semaglutide in Patients With Alzheimer's Disease

2026-09-01

Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited. Growing evidence suggests that inflammation in the brain and the body plays a key role in the onset and progression of AD. In particular, immune cells called regulatory T cells (Tregs), which normally help control inflammation, are impaired in AD individuals. This leads to increased activity of harmful immune pathways that worsen brain injury. Interleukin-2 (IL-2) is a drug that can restore the function of Tregs. Glucagon-like

A Prospective, Multicenter, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus

2026-08-09

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an approved and well-established therapy for type 2 diabetes mellitus (T2DM), providing both robust glycemic control and weight reduction. Semaglutide Depot, is a long-acting formulation of semaglutide, designed for once every four weeks administration, intended to reduce treatment burden, and improve adherence supporting sustained glycemic control over time. This Phase I/Ila dose escalation study design to evaluate the safety, tolerability, pharmacokinetics and efficacy of Semaglutide Depot in adults with T2DM.

A Randomized Controlled Trial Evaluating Electroacupuncture, Acupoint Injection, and Acupressure Massage for Motor and Swallowing Rehabilitation in Patients With Post-Acute Ischemic Stroke

2026-12-01

Objective: To assess the therapeutic efficacy of combined electroacupuncture (or electric field acupuncture), hydroacupuncture (Cerebrolysin or B-complex vitamins), and acupressure massage in restoring motor function and treating dysphagia in post-acute ischemic stroke patients, while evaluating safety profiles and prognostic factors associated with clinical outcomes. Interventions: Participants will be randomly assigned to one of four treatment arms: Group 1: Electric field acupuncture + Cerebrolysin Acupoint injection + acupressure massage Group 2: Electric field acupuncture + B-complex v

Afamelanotide

Reactions Weekly · 2026-03-21

Apoptosis Modulation by LL-37: From Mitochondrial Cell Death to Prosurvival Signaling.

International journal of molecular sciences · 2026

This review summarizes current knowledge on the role of human cathelicidin LL-37 in the regulation of apoptosis. LL-37 can modulate programmed cell death pathways, exerting either proapoptotic or antiapoptotic effects depending on various factors, such as cell type and peptide concentration. Data on LL-37 derivatives and their involvement in apoptosis are also discussed. Understanding the molecular mechanisms underlying LL-37 regulation of apoptosis is necessary to expand the therapeutic potential of this peptide in various pathological conditions, including cancer.

BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence.

International journal of molecular sciences · 2026

Ischemia-reperfusion injury (IRI) is a clinically important consequence of blood-flow restoration after ischemia and contributes to tissue damage across multiple organ systems. This critical review evaluates the preclinical evidence for BPC 157 in rodent IRI and related reperfusion-associated vascular injury models, with particular attention to oxidative stress, endothelial and nitric oxide (NO)-related responses, inflammation, apoptosis, angiogenic signaling, and tissue injury. Searches were performed up to 24 June 2026 across PubMed/MEDLINE, Web of Science Core Collection, Scopus, PMC, publi

Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.

Nature metabolism · 2026

Peptide multi-receptor agonists have advanced obesity treatment, yet challenges remain in achieving maximal weight loss and metabolic control, especially in patients with obesity and type 2 diabetes. Here we demonstrate enhanced metabolic benefits of a combination therapy with retatrutide, a unimolecular GLP-1R/GIPR/GCGR tri-agonist, and cagrilintide, an AMLNR/CALCR co-agonist, in diet-induced obese male rats. Daily co-administration produces dose-dependent reductions in body weight and food intake that exceed both equimolar monotherapies and matched-dose comparator combinations incorporating

Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.

Pharmaceuticals (Basel, Switzerland) · 2026

Combinatorial therapy of LL-37 and ADSCs accelerates diabetic wound repair by orchestrating NRROS-mediated crosstalk between TGF-β/SMAD and hippo/TEAD1 axes.

Cytokine · 2026

Diabetic wounds pose a significant therapeutic challenge. While the antimicrobial peptide LL-37 and adipose-derived stem cells (ADSCs) individually show potential for wound repair, the efficacy and mechanism of their combined treatment remain unclear. This study aimed to investigate the therapeutic effect of LL-37 combined with ADSCs on diabetic wound healing. Clinical samples from diabetic and non-diabetic patients were analyzed, combined with bioinformatics analysis of public datasets (GSE144441 and GSE182906) to identify key genes. A diabetic mouse wound model was established to validate th

Composite pheochromocytoma-ganglioneuroma secreting vasoactive intestinal peptide.

Endocrinology, diabetes & metabolism case reports · 2026

An 80-year-old female patient presented with a 10-year history of progressively worsening diarrhea and chronic hyponatremia. An abdominal computed tomography (CT) revealed a 6.8-centimeter right adrenal mass. A Ga-68 DOTATATE positron emission tomography (PET)/CT scan subsequently demonstrated a significant expression of somatostatin receptors on the tumoral shell (maximal SUV of 14.4), associated with a hypometabolic central portion. Endocrine investigation indicated elevated levels of both urinary and plasmatic normetanephrines. Given the watery diarrhea, VIP levels were measured, which were

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.

Journal of the American College of Cardiology · 2026

Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for treatment of type 2 diabetes and obesity. The effect of tirzepatide on cardiovascular risk biomarkers in people with overweight or obesity remains uncertain.

Dietary Pistachio Intake and Nutrition-Related Outcomes in Individuals Using GLP-1 Receptor Agonists: A Randomized Controlled Trial

2026-01-29

In this study will look at how eating pistachios every day might affect participants weight, how healthy their diet is, and how they feel when eating. Investigators want to see if adding pistachios to meals for 12 weeks helps participants feel fuller, have more energy, and improve body composition. The study will include adults who have been taking GLP-1 medicines like semaglutide or tirzepatide for at least three months. Investigators also want to see if eating pistachios improves overall diet quality and health markers like tiredness and certain levels in blood.

Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.

The lancet. Diabetes & endocrinology · 2026

The GLP-1 receptor agonist semaglutide reduces clinically important kidney outcomes in people with type 2 diabetes and chronic kidney disease (CKD). We aimed to assess the pooled effects of semaglutide on kidney outcomes in prespecified analyses of participant-level data from the diverse populations of the SELECT, FLOW, and SOUL randomised placebo-controlled trials.

Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide: A Multicenter, Prospective, Randomized Controlled Trial (IIT)

2026-09-15

This is a multicenter, prospective, randomized controlled investigator-initiated trial (IIT) aimed at evaluating the efficacy and safety of switching to mazdutide therapy in patients with type 2 diabetes mellitus (T2DM) and moderate-to-severe non-alcoholic fatty liver disease (NAFLD) who have achieved glycemic control. Chinese patients with type 2 diabetes mellitus (T2DM) are susceptible to visceral fat accumulation, which increases the risk of cardiometabolic diseases and mortality. Metabolic associated fatty liver disease (MAFLD) is highly prevalent among Chinese T2DM patients, and the coex

Efficacy and Safety of Mazdutide Injection for the Treatment of Overweight Patients With Compensated Cirrhosis and Clinically Significant Portal Hypertension

2026-09-01

Obesity and metabolic abnormalities accelerate decompensation in compensated cirrhosis, driven by clinically significant portal hypertension (CSPH, HVPG≥10 mmHg). Lifestyle-induced weight loss can lower portal pressure, but pharmacological options are limited. Mazdutide, a dual GLP-1/glucagon receptor agonist, has proven weight-loss and glycaemic benefits, yet its safety and efficacy in cirrhosis with portal hypertension are unknown. This investigator-initiated, single-arm, open-label, exploratory trial evaluates whether mazdutide can safely reduce portal pressure in overweight patients with c

Enzymatic Stability and Comparative Effects of Kisspeptin-14, Kisspeptin-13 and Kisspeptin-10 on Beta-Cell Function, Glucose Homeostasis and Appetite Regulation.

Metabolites · 2026

Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity: A Double-Blinded Randomized Controlled Trial

2026-07-18

The goal of this clinical trial is to learn if tirzepatide works to improve physical function in adults with heart failure and obesity. It will also learn about the safety of tirzepatide. The main questions it aims to answer are: Does tirzepatide improve how far participants can walk in 6 minutes? Does tirzepatide improve heart failure symptoms and quality of life? What side effects do participants have when taking tirzepatide? Researchers will compare tirzepatide to a placebo (a look-alike substance that contains no drug) to see if tirzepatide improves physical function in people with heart

FOXO4-DRI as a Unified Cancer Platform: A Proposed Framework for Prevention, Treatment, and Stopping Cancer from Coming Back

Zenodo (CERN European Organization for Nuclear Research) · 2026-08-04

FOXO4-DRI as a Unified Cancer Platform: A Proposed Framework for Prevention, Treatment, and Stopping Cancer from Coming Back

Zenodo (CERN European Organization for Nuclear Research) · 2026-08-04

GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.

Pharmaceutics · 2026

How effective is KPV in the treatment of MCAS?

Zenodo (CERN European Organization for Nuclear Research) · 2026-08-03

How effective is KPV in the treatment of MCAS?

Zenodo (CERN European Organization for Nuclear Research) · 2026-08-03

Kisspeptin-10 Alleviates Obesity-induced Testicular Oxidative Stress and Mitochondrial Dysfunction via Modulation of Mitophagy and Autophagy Signaling.

Reproductive sciences (Thousand Oaks, Calif.) · 2026

Obesity impairs male reproductive function via oxidative stress and mitochondrial dysfunction. Kisspeptin-10 may regulate redox balance and mitochondrial homeostasis, but its role in obesity-related testicular dysfunction remains unclear. This study aimed to investigate whether Kisspeptin-10 ameliorates obesity-induced testicular oxidative stress and sperm dysfunction, with particular emphasis on mitophagy, autophagy, and apoptosis-related pathways. Forty male Sprague Dawley rats were divided into four groups: Control, Obesity, Kisspeptin-10, and Obesity+Kisspeptin-10. Obesity was induced by f

Late-life semaglutide treatment slows ageing and extends lifespan in female mice.

Nature · 2026

Pharmacological glucagon-like peptide-1 receptor (GLP-1R) activation reduces food intake and is an effective therapy for type 2 diabetes and obesity

Mazdutide and the metabolic treatment revolution

Trends Open · 2026-08-01

Melanotan ii

Reactions Weekly · 2026-03-26

Mitochondrial Quality Control in Inherited Mitochondrial Cardiomyopathy: Convergent Pathobiology and a Testable Therapeutic Framework.

International journal of molecular sciences · 2026

Inherited mitochondrial cardiomyopathies arise from pathogenic variants affecting oxidative phosphorylation, mitochondrial DNA maintenance, cardiolipin remodeling, protein import, cofactor metabolism, and mitochondrial dynamics or proteostasis. These disorders may be cardiac-predominant or part of multisystem disease. Their overlapping cardiac phenotypes suggest convergence on interacting pathways of energetic stress, cristae disruption, calcium imbalance, and redox injury, but do not establish a universal requirement for defective mitophagy. Mitochondrial quality control encompasses protein s

Mitokines as bioenergetic stress signals in cardiovascular disease: mitochondrial communication, endocrine adaptation, and translational implications.

Journal of bioenergetics and biomembranes · 2026

Cardiovascular disease is strongly influenced by mitochondrial dysfunction, yet how mitochondrial stress is communicated beyond the affected cell to coordinate systemic responses remains incompletely understood. Mitokines are stress-responsive signaling factors that link mitochondrial perturbation to cellular and interorgan adaptation. These include nuclear-encoded proteins such as fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15), as well as mitochondrial-derived peptides including Humanin and MOTS-c. This review critically examines mitokine regulation and signa

MOTS-c mediates remote ischemic preconditioning-induced protection against lung ischemia-reperfusion injury via NRF2-dependent mitochondrial biogenesis.

Chinese medical journal · 2026

Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.

Diabetes, obesity & metabolism · 2026

Survodutide is a novel long-acting dual glucagon (GCGR)/glucagon-like peptide-1 (GLP-1R) receptor agonist currently in phase-3 clinical development for the treatment of people living with obesity and metabolic dysfunction-associated steatohepatitis. Emerging evidence suggests impaired renal GCGR function in chronic kidney disease (CKD), including diabetic kidney disease (DKD). This study aimed to characterize the effects of survodutide in a translational mouse model of advanced DKD, induced by adeno-associated virus-mediated renin overexpression (ReninAAV) in uninephrectomized (UNx) diabetic d

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.

Diabetes, obesity & metabolism · 2026

This study aimed to indirectly compare the effects of oral semaglutide 25 mg versus orforglipron 36 mg on body weight loss, other cardiometabolic biomarkers, and tolerability in adults with overweight (body mass index [BMI] ≥ 27 kg/m

Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.

The American journal of psychiatry · 2026

Accumulating preclinical and observational evidence suggests that glucagon-like peptide-1 receptor agonists, including semaglutide, reduce alcohol consumption. This phase 2 double-blind, randomized, parallel-arm trial evaluated the effects of oral semaglutide on alcohol craving and consumption among treatment-seeking adults with alcohol use disorder (AUD).

Oxytocin suppresses endothelial-to-mesenchymal transition to mitigate cardiac fibrosis via the eNOS/cGMP/PKG pathway.

Biochemical pharmacology · 2026

Cardiac fibrosis is a major pathological feature that contributes to the development and progression of heart failure. Endothelial-to-mesenchymal transition (EndMT) is increasingly recognized as an important driver of cardiac fibrosis; however, its regulatory mechanisms remain incompletely understood. Oxytocin (OT) has been reported to exert cardioprotective effects, but whether it modulates EndMT and the underlying signaling pathways requires further investigation. To address this question, a rat model of isoproterenol (ISO)-induced cardiac fibrosis was established. Cardiac structure and func

Role of Oxytocin in Obesity.

Current diabetes reports · 2026

This review will summarize the role of the hormone, oxytocin (OT), in the control of energy balance and glucose homeostasis in pre-clinical and clinical models and the role of sex in contributing to these effects.

Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.

Diabetes, obesity & metabolism · 2026

Tirzepatide, a first-in-class dual GIP/GLP-1 receptor agonist, was approved by the FDA for type 2 diabetes mellitus (2022) and chronic weight management (2023). Despite superior efficacy in trials, its real-world safety profile remains incompletely characterised. This study aimed to characterise tirzepatide's post-marketing safety signals using the FAERS database.

Solid-State Fermentation Drives L-Carnitine Accumulation and Isoflavone Bioconversion with Functional Enhancement in Soybean.

Journal of microbiology and biotechnology · 2026

Solid-state fermentation (SSF) is widely used to enhance the functional properties of plant-based substrates. In this study, soybean powder was used as a substrate for SSF with

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

The New England journal of medicine · 2026

For persons living with both type 2 diabetes and obesity, weight management may be the most effective therapy for type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have potent weight-reducing effects, and other mechanisms may confer additional benefits. Survodutide is an investigational glucagon receptor-GLP-1 receptor dual agonist with potential weight-reducing and metabolic benefits.

Synchronizing obesity management with survodutide

Exploration of Drug Science · 2026-08-17

Targeted delivery of antimicrobial peptide LL-37 via ferritin fusion improves antibacterial and anti-inflammatory outcomes in a murine sepsis model.

International journal of biological macromolecules · 2026

The antimicrobial peptide LL-37 holds considerable therapeutic potential for treating infection and inflammation; however, its clinical application is often limited by poor stability, susceptibility to proteolytic degradation, and insufficient targeting capability. In this study, we engineered a targeted fusion protein (designated as FL) based on ferritin light chain (FTL) by genetically fusing the LL-37 peptide to the C-terminus of FTL, thereby markedly enhancing the structural stability and proteolytic resistance of LL-37. This design further exploits the specific recognition of FTL by scave

Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress.

Physiological research · 2026

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a major cause of cirrhosis, liver cancer, and cardiovascular disease. Early mitochondrial dysfunction drives lipid imbalance, inflammation, and fibrosis. Given the lack of approved pharmacological treatments, this study compares the mitochondria-targeted agents MitoQ and SS-31 for their effects on mitochondrial function, oxidative stress, apoptosis, and inflammation in aged, nutritionally stressed mice with MASLD. Aged female C57BL/6 mice (12-14 months) were fed a high-fat, high-fructose diet for 16 weeks to induce MASLD. Mice

The Gut-Heart-Kidney Axis in Heart Failure: Trimethylamine N-Oxide and Beyond-A State-of-the-Art Review.

Biomedicines · 2026

Trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite of dietary choline and L-carnitine, has emerged as a leading molecular mediator of the gut-heart-kidney axis in heart failure (HF). This state-of-the-art narrative review synthesizes evidence from 14 observational studies (13 prospective cohorts and one cross-sectional analysis), encompassing a heterogeneous range of HF settings, including established chronic HF, acute decompensated HF, incident HF in community cohorts, and subclinical myocardial injury. Across these populations, elevated circulating TMAO has been associated wi

The Oxidative-Mitochondrial-Inflammatory Axis in Retinitis Pigmentosa: Extracellular mtDNA as Biomarker and Therapeutic Read-Out.

Antioxidants (Basel, Switzerland) · 2026

Retinitis pigmentosa (RP) is the most common inherited retinal dystrophy (prevalence ~1:4000) and a leading Mendelian cause of working-age blindness. Despite marked genetic heterogeneity, its progression converges on a common secondary cascade of outer-retinal hyperoxia, increased reactive oxygen species (ROS), and mitochondrial dysfunction that drives cone degeneration and central vision loss. Because this oxidative cascade is largely genotype-independent and pharmacologically tractable, oxidative stress is a cross-cutting therapeutic target. Within it, mitochondrial DNA (mtDNA) is a key elem

Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review

Preprints.org · 2026-05-18

Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.

BMJ (Clinical research ed.) · 2026

To estimate the magnitude of reduction in major adverse cardiovascular events (MACE) that would be observed in clinical practice from adding tirzepatide to standard of care treatment.

Tirzepatide for Treatment of CCCA

2026-09-15

The goal of this pilot clinical trial is to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults. The main questions it aims to answer are: * Does tirzepatide improve the symptoms and signs of active CCCA? * Does tirzepatide change the activity of genes in the scalp, especially genes related to scarring? * Does tirzepatide promote hair regrowth? Participants will: * Inject tirzepatide once a week for 12 months. * Visit the clinic for scalp examinations, photographs, and other health assessments. * Have scalp

Transcriptomic Effects of Peptide Drug Selank during Early Experimental Cerebral Ischemia in Rats

Molecular Biology · 2026

In the treatment of ischemic stroke, much attention is paid to neuroprotective therapy aimed at maintaining the viability and restoring the functions of nervous system cells. The peptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is an analog of endogenous tuftsin and is used as a drug that affects the human nervous system. Selank exerts anxiolytic, nootropic, neuroprotective, and immunomodulatory effects. However, its neuroactivity may be broader and manifest itself in conditions of severe damage to neurological functions, such as stroke. A magnetic resonance imaging-guided transient middle cerebra